124 related articles for article (PubMed ID: 20398626)
1. Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells.
Shi L; Song Q; Zhang Y; Lou Y; Wang Y; Tian L; Zheng Y; Ma D; Ke X; Wang Y
Biochem Biophys Res Commun; 2010 May; 396(2):224-30. PubMed ID: 20398626
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Chen C; Zhou H; Xu L; Xu D; Wang Y; Zhang Y; Liu X; Liu Z; Ma D; Ma Q; Chen Y
Apoptosis; 2010 Jul; 15(7):805-13. PubMed ID: 20349137
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated PDCD5 gene transfer sensitizes K562 cells to apoptosis induced by idarubicin in vitro and in vivo.
Ruan GR; Zhao HS; Chang Y; Li JL; Qin YZ; Liu YR; Chen SS; Huang XJ
Apoptosis; 2008 May; 13(5):641-8. PubMed ID: 18401719
[TBL] [Abstract][Full Text] [Related]
4. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR
Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo.
Wang L; Wang C; Su B; Song Q; Zhang Y; Luo Y; Li Q; Tan W; Ma D; Wang L
Biochem Cell Biol; 2013 Dec; 91(6):526-31. PubMed ID: 24219296
[TBL] [Abstract][Full Text] [Related]
6. Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo.
Yin A; Jiang Y; Zhang X; Zhao J; Luo H
Eur J Pharmacol; 2010 Dec; 649(1-3):120-6. PubMed ID: 20869960
[TBL] [Abstract][Full Text] [Related]
7. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo.
Chun-Guang W; Jun-Qing Y; Bei-Zhong L; Dan-Ting J; Chong W; Liang Z; Dan Z; Yan W
Eur J Pharmacol; 2010 Feb; 627(1-3):33-41. PubMed ID: 19857484
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
11. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
[TBL] [Abstract][Full Text] [Related]
13. Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells.
Wang X; Ren J; Qu X
ChemMedChem; 2008 Jun; 3(6):940-5. PubMed ID: 18286553
[TBL] [Abstract][Full Text] [Related]
14. [Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo].
Zhou YL; Hu WX; Lü YP; Qiu LN; Wang WS; Yang ZY; Liu JD; Rao GW
Yao Xue Xue Bao; 2007 Jan; 42(1):26-34. PubMed ID: 17520803
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
16. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
Ruan GR; Qin YZ; Chen SS; Li JL; Ma X; Chang Y; Wang YZ; Fu JY; Liu YR
Leuk Res; 2006 Sep; 30(9):1159-65. PubMed ID: 16507320
[TBL] [Abstract][Full Text] [Related]
17. Effect of antisense VEGF cDNA transfection on the growth of chronic myeloid leukemia K562 cells in vitro and in nude mice.
Ruan GR; Liu YR; Chen SS; Fu JY; Chang Y; Qin YZ; Li JL; Yu H; Wang H
Leuk Res; 2004 Jul; 28(7):763-9. PubMed ID: 15158098
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells.
Yang YC; Huang WF; Chuan LM; Xiao DW; Zeng YL; Zhou DA; Xu GQ; Liu W; Huang B; Hu Q
Chemotherapy; 2008; 54(6):438-46. PubMed ID: 18824851
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Guo QL; Wu MS; Chen Z
Acta Pharmacol Sin; 2002 Oct; 23(10):946-51. PubMed ID: 12370101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
